Other tissues that have been shown to express TMEM217 include: connective tissues, the liver, mammary glands, the testis, and the cervix. Co-expression analyses have found that TMEM217 was up-regulated in response to mechanical stretch in dermal fibroblast cells and in response to the resveratrol derivative, DMU-212, in vascular endothelial tissues. No known function has been attributed to TMEM217, however a co-expression analysis in dermal fibroblasts has predicted the protein to have a potential association with the cytoskeleton. Single nucleotide polymorphisms in TMEM217 have been linked to Alzheimer’s disease and diabetic retinopathy. TMEM217 was also found to have similar expression patterns as TRPM2, a biomarker linked to breast carcinoma. Expression profiles have also linked elevated TMEM217 expression to bladder cancer and lymphoma. TMEM217 was found to have orthologs in organisms as early as the scaled fish, which diverged 420 million years ago. Although found in organisms as early as fish and reptiles, TMEM217 has no known orthologs in any bird species. TMEM217 has no known paralogs.